2023 World Conference on Lung Cancer (Posters)-EP12.01. Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report

EP12.01. Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report - PDF(Slides)

Back to course

Pdf Summary

A case report published in the International Journal of Surgery Case Reports highlights the successful transformation of unresectable advanced non-small cell lung cancer (NSCLC) into resectable NSCLC through effective neoadjuvant therapy with a drug called aumolertinib. The patient was initially diagnosed with stage IIIC NSCLC and received icotinib treatment, but experienced disease progression. Genetic testing revealed that the patient had an EGFR exon 19 deletion and acquired T790M mutation. Subsequently, the patient was treated with aumolertinib and achieved significant tumor shrinkage, leading to a downstaging of the cancer. This allowed the patient to become eligible for surgery. In December 2021, the patient underwent lobectomy and lymph node dissection, with clear margins and no tumor involvement found in the postoperative pathology. The patient is currently in follow-up visits and has shown no evidence of recurrence or metastasis.<br /><br />The case demonstrates that neoadjuvant therapy with aumolertinib, a third-generation EGFR-TKI, can effectively transform initially unresectable advanced NSCLC into resectable NSCLC. The treatment resulted in excellent tumor remission and a favorable safety profile throughout the perioperative phases. The case report suggests that this approach can extend the progression-free survival and improve the clinical outcomes for patients with unresectable advanced EGFR-mutant NSCLC. The researchers emphasize the importance of effective neoadjuvant therapy in the management of stage III NSCLC, as it can lead to the transformation of unresectable tumors into surgically resectable ones, providing patients with the opportunity to benefit from prolonged progression-free survival. Further studies are warranted to confirm the efficacy of aumolertinib in preoperative induction therapy for NSCLC.

Asset Subtitle

Cheng Chen

Meta Tag

Speaker Cheng Chen

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

case report

neoadjuvant therapy

unresectable advanced non-small cell lung cancer

NSCLC

aumolertinib

EGFR exon 19 deletion

T790M mutation

tumor shrinkage

lobectomy

follow-up visits